Precision BioSciences
DTIL
100 hedge funds and large institutions have $60.9M invested in Precision BioSciences in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 35 reducing their positions, and 17 closing their positions.
86% more call options, than puts
Call options by funds: $26K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
0.58% less ownership
Funds ownership: 46.72% → 46.15% (-0.58%)
2% less funds holding
Funds holding: 102 → 100 (-2)
11% less capital invested
Capital invested by funds: $68.6M → $60.9M (-$7.7M)
37% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$630K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$520K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$393K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.8M |
| 2 |
Millennium Management
New York
|
-$1.12M |
| 3 |
BlackRock
New York
|
-$874K |
| 4 |
Renaissance Technologies
New York
|
-$780K |
| 5 |
Morgan Stanley
New York
|
-$339K |
DTIL Hedge Fund Activity: Q4 2022 in Review
100 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q4 2022, worth a combined $60.9M — down 11% from $68.6M a quarter earlier.
Fund positioning in DTIL was balanced in Q4 2022: 17 funds opened new positions, 17 closed out, 22 added to existing stakes and 35 trimmed.
The largest buyer was Great Point Partners, adding an estimated $1.44M. The largest seller was Marshall Wace, cutting an estimated $1.8M.
- 100 institutional investors held Precision BioSciences (DTIL) as of Q4 2022, down from 102 in Q3 2022.
- Funds reported $60.9M of Precision BioSciences stock for Q4 2022, down 11% quarter-over-quarter.
- 17 funds opened new Precision BioSciences positions in Q4 2022 and 17 closed out, a net change of 0 holders.
- The largest Precision BioSciences buyer in Q4 2022 was Great Point Partners, an estimated $1.44M added.
- The largest Precision BioSciences seller in Q4 2022 was Marshall Wace, an estimated $1.8M sold.
Based on aggregated 13F filings for Q4 2022.